Infection

13
Pipeline Programs
12
Companies
34
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
1
0
2
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 17 programs with unclassified modality

On Market (1)

Approved therapies currently available

Bayer
CIPROApproved
ciprofloxacin
Bayer
oral1997

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
7 programs
3
1
MagnexPhase 41 trial
MoxidectinPhase 11 trial
metronidazole IV 500 mgPhase 11 trial
moxidectinPhase 11 trial
Changing Patterns of Candida Infections in Urban Medical CentersN/A1 trial
+2 more programs
Active Trials
NCT00366223Completed80Est. Jun 2017
NCT03923426Completed572Est. Mar 2022
NCT00488488Completed1,028Est. Mar 2010
+4 more trials
Bayer
BayerLEVERKUSEN, Germany
1 program
1
CIPRO(Ciprofloxacin)N/ASmall Molecule5 trials
Active Trials
NCT02555059Completed48Est. Jun 2019
NCT01561794Completed44Est. Mar 2015
NCT01538667Completed24Est. Jul 2012
+2 more trials
M&
Merck & Co.RAHWAY, NJ
1 program
1
MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 DaysPhase 41 trial
Active Trials
NCT00445094Completed120Est. Jan 2007
Sanofi
SanofiPARIS, France
1 program
1
TeicoplaninPhase 42 trials
Active Trials
NCT04003818Terminated50Est. Mar 2021
NCT00454272Completed197Est. Aug 2007
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
leukocyte depletion of whole bloodPhase 41 trial
Active Trials
NCT00176124Completed1,089Est. Sep 2005
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
Hantavax injectionPhase 31 trial
Active Trials
NCT02360514CompletedEst. Oct 2012
VP
1 program
1
Pegylated Interferon Alfa 2aPhase 31 trial
Active Trials
NCT01821963Terminated1Est. Feb 2014
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
1
caspofungin acetatePhase 21 trial
Active Trials
NCT00238355Terminated13Est. Jun 2008
Sandoz
SandozAustria - Kundl
2 programs
2
Azithromycin Monohydrate 600 mg TabletsPhase 1
Azithromycin Monohydrate 600mg Tablets Geneva PharmaceuticalsPhase 1
Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
1 program
Home hospitalizationN/A1 trial
Active Trials
NCT03203759CompletedEst. May 2018
Plus Therapeutics
1 program
Novel Microbicidal Liquid PolymerN/A1 trial
Active Trials
NCT03756506CompletedEst. Sep 2019
Abbott
AbbottABBOTT PARK, IL
1 program
Procurement of Human Specimens for the Evaluation of Early Markers of SepsisN/A1 trial
Active Trials
NCT01746407Completed872Est. Dec 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiTeicoplanin
Merck & Co.MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days
SanofiTeicoplanin
PfizerMagnex
BayerCiprofloxacin
BayerCiprofloxacin
BayerCiprofloxacin
BayerCiprofloxacin
Heidelberg Pharmaleukocyte depletion of whole blood
Vertex PharmaceuticalsPegylated Interferon Alfa 2a
BayerCiprofloxacin
GC BiopharmaHantavax injection
BayerCiprofloxacin
BayerCiprofloxacin
BayerCiprofloxacin

Showing 15 of 34 trials with date data

Clinical Trials (34)

Total enrollment: 18,919 patients across 34 trials

Efficacy and Safety of Teicoplanin in CDAD

Start: May 2020Est. completion: Mar 202150 patients
Phase 4Terminated
NCT00445094Merck & Co.MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days

A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

Start: Nov 2006Est. completion: Jan 2007120 patients
Phase 4Completed

Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients

Start: Jan 2005Est. completion: Aug 2007197 patients
Phase 4Completed

A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections

Start: Jul 2004Est. completion: Apr 2005307 patients
Phase 4Completed
NCT00481689BayerCiprofloxacin

Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

Start: May 2004Est. completion: Sep 2005500 patients
Phase 4Completed
NCT00669994BayerCiprofloxacin

Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections

Start: Jul 2003Est. completion: Oct 2003180 patients
Phase 4Completed
NCT00676533BayerCiprofloxacin

Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections

Start: Jun 2003Est. completion: Jan 2004276 patients
Phase 4Completed
NCT00663806BayerCiprofloxacin

A Phase IV Study of Cipro XR in Uncomplicated UTI

Start: Feb 2003Est. completion: Jul 20037,614 patients
Phase 4Completed
NCT00176124Heidelberg Pharmaleukocyte depletion of whole blood

Leukocyte Depletion of Autologous Whole Blood

Start: Apr 2001Est. completion: Sep 20051,089 patients
Phase 4Completed
NCT01821963Vertex PharmaceuticalsPegylated Interferon Alfa 2a

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Start: Apr 2013Est. completion: Feb 20141 patients
Phase 3Terminated
NCT01561794BayerCiprofloxacin

A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia

Start: May 2012Est. completion: Mar 201544 patients
Phase 3Completed
NCT02360514GC BiopharmaHantavax injection

Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS

Start: Dec 2007Est. completion: Oct 2012
Phase 3Completed
NCT00137787BayerCiprofloxacin

Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases

Start: Apr 2005Est. completion: May 201051 patients
Phase 3Completed
NCT00670215BayerCiprofloxacin

BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis

Start: Apr 2004Est. completion: Oct 2004497 patients
Phase 3Completed
NCT00668122BayerCiprofloxacin

Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections

Start: Mar 2004Est. completion: Jan 2006212 patients
Phase 3Completed
NCT00668044BayerCiprofloxacin

Ciprofloxacin on Burned Patients

Start: Nov 2002Est. completion: Nov 200318 patients
Phase 3Completed
NCT00761462BayerCiprofloxacin

BAY 0 9867 Cipro Pediatric Use Study (QUIP)

Start: Oct 1999Est. completion: Jan 20081,029 patients
Phase 3Completed

Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

Start: Aug 2003Est. completion: Jun 200813 patients
Phase 2Terminated
NCT01538667BayerCiprofloxacin

Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases

Start: Apr 2012Est. completion: Jul 201224 patients
Phase 1Completed
NCT01407016Pfizermetronidazole IV 500 mg

A Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Injection In Healthy Japanese Subjects

Start: Aug 2011Est. completion: Sep 20116 patients
Phase 1Completed
NCT01168895BayerCiprofloxacin

Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder

Start: Jul 2010Est. completion: Sep 201012 patients
Phase 1Completed
NCT01072942BayerCiprofloxacin

To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)

Start: Jan 2010Est. completion: Jul 201016 patients
Phase 1Completed
NCT00910351BayerCiprofloxacin

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Start: Jul 2009Est. completion: Oct 201019 patients
Phase 1Completed

Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women

Start: Nov 2008Est. completion: Sep 200912 patients
Phase 1Completed

Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of Moxidectin

Start: Nov 2008Est. completion: May 200954 patients
Phase 1Completed
NCT03923426PfizerZavicefta Treatment

Real-World Observational Study Of Zavicefta to Characterize Use Patterns

Start: Nov 2018Est. completion: Mar 2022572 patients
N/ACompleted
NCT03756506Plus TherapeuticsNovel Microbicidal Liquid Polymer

The Use of a Novel Microbicidal Liquid Polymer for the Reduction of Pin Track Infection

Start: Nov 2018Est. completion: Sep 2019
N/ACompleted
NCT03203759Connect BiopharmaHome hospitalization

Hospital-Level Care at Home for Acutely Ill Adults

Start: Jun 2017Est. completion: May 2018
N/ACompleted
NCT02555059BayerCiprofloxacin

Special Drug Use Investigation of Ciproxan Injection in Pediatrics

Start: Jul 2016Est. completion: Jun 201948 patients
N/ACompleted
NCT01746407AbbottProcurement of Human Specimens for the Evaluation of Early Markers of Sepsis

Procurement of Human Specimens for the Evaluation of Early Markers of Sepsis

Start: Dec 2012Est. completion: Dec 2014872 patients
N/ACompleted
NCT01690559BayerCiprofloxacin

Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution

Start: Apr 2010Est. completion: Jan 2012704 patients
N/ACompleted
NCT01670435BayerCiprofloxacin

Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance

Start: May 2007Est. completion: Oct 20103,274 patients
N/ACompleted

A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting

Start: Nov 2006Est. completion: Mar 20101,028 patients
N/ACompleted
NCT00366223PfizerChanging Patterns of Candida Infections in Urban Medical Centers

Changing Patterns of Candida Infections in Urban Medical Centers

Start: Aug 2006Est. completion: Jun 201780 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
12 companies competing in this space